Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for Buccal delivery and treatment of patients with atherosclerosis

Drug Development and Industrial Pharmacy

Volumn 39, Issue 5, 2013, Pages 670-680

  Yedurkar, Pramod ^a   Dhiman, Munish Kumar ^a   Petkar, Kailash ^a   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Bilayer; Buccal; Mucosal drug delivery; Pharmacokinetics pharmacodynamics; Sustained release

Indexed keywords

BIOPOLYMER; CARBOMER; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HYPERLIPIDEMIA; MALE; MUCOADHESION; NONHUMAN; PH; RABBIT; SUSTAINED DRUG RELEASE; SWELLING; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACRYLATES; ADMINISTRATION, BUCCAL; ANIMALS; AREA UNDER CURVE; ATHEROSCLEROSIS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METHYLCELLULOSE; MOUTH MUCOSA; PRAVASTATIN; RABBITS; SOLUBILITY;

EID: 84875889503     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.687379     Document Type: Article

References (49)

1. Maurya SK, Pathak K, Bali V. (2010). Therapeutic potential of mucoadhesive drug delivery systems-an updated patent review. Recent Pat Drug Deliv Formul, 4:256-265.
2. Rathbone M, Drummond B, Tucker B. (1994). The oral cavity as a site for systemic drug delivery. Adv Drug Deli Rev, 13: 1-22.
3. Squier CA, Wertz PW. (1999) Structure and function of the oral mucosa and implications for drug delivery. In Rathbone MJ: (eds). Oral mucosal drug delivery. Marcel Dekker. Inc. New York. 1-26.
4. Nagai T, Konishi R. (1987). Buccal/gingival drug delivery systems. J Control Rel. 6, 353-360.
5. Ishida M, Nambu N, Nagai T. (1983). Ointment-type oral mucosal dosage form of Carbopol containing prednisolone for treatment of aphtha. Chem Pharm Bull, 31:1010-1014.
6. Gurny R, Meyer JM, Peppas NA. (1984). Bioadhesive intraoral release systems: Design, testing and analysis. Biomaterials, 5:336-340.
7. Ponchel G, Touchard F, Duchene D, Peppas NA. (1987). Bioadhesive analysis of controlled-release systems: I Fracture and interpretation analysis in poly (acrylic acid) containing systems. J Control Rel, 5:129-141.
8. Berthold A, Cremer K, Kreuter J. (1996). Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J Control Rel, 39: 17-25.
9. Voorspoels J, Remon JP, Eechaute W, De Sy W. (1996). Buccal absorption of testosterone and its esters using a bioadhesive tablet in dogs. Pharm Res, 13:1228-1232.
10. Senel S, Ikinci G, Kas S, Yousefi-Rad A, Sargon MF, Hincal AA. (2000). Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharm, 193:197-203.
11. Yajaman S, Ketousetuo K, Bandyopadhyay AK. (2006) Buccal bioadhesive drug delivery - A promising option for orally less efficient drugs. J Controll Rel. 114: 15-40.
12. Llabot JM, Manzo RH, Allemandi DA. (2002). Doublelayered mucoadhesive tablets containing nystatin. AAPS PharmSciTech, 3:E22.
13. Tsujita Y, Watanabe Y. (1989). Pravastatin sodium: A novel cholesterol-lowering agent that inhibits hmg-coa reductase. Cardiovascular Drug Reviews. 7: 110-126.
14. Kumar M, Talwar N, Raghuvanshi RS, Rampal AS. (2005). Controlled release drug delivery system of pravastatin, US Patent 0089572 A1.
15. Boyong LI, Nangia A, Dely A, Wong D. (2003). Stable pharmaceutical compositions containing pravastatin, WO Patent 03/000239.
16. Shidhaye SS, Thakkar PV, Dand NM, Kadam VJ. (2010). Buccal drug delivery of pravastatin sodium. AAPS PharmSciTech, 11: 416-424.
17. Jani GK, Shah DP, Prajapati VD, Jain VC. (2009). Gums and mucilages: versatile excipients for pharmaceutical formulations. Asian J Pharmaceut Sci. 4: 309-323.
18. Nafee NA, Boraie MA, Ismail FA, Mortada LM. (2003). Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm, 53:199-212.
19. Cui Z, Mumper RJ. (2002). Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. Pharm Res, 19:1901-1906.
20. Peh KK, Wong CF. (1999). Polymeric films as vehicle for buccal delivery: Swelling, mechanical, and bioadhesive properties. J Pharm Pharm Sci, 2:53-61.
21. Kawabata K, Matsushima N, Sasahara K. (1998). An automated method for the simultaneous determination of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Biomed Chromatogr, 12:271-275.
22. Bottenberg P, Cleymaet R, Muynek CD, Remon JP, Coomans D, Slop D. (1991). Development and testing of bioadhesive, fluoridecontaining slow-release tablets for oral use. J Pharm Pharmacol, 43:457-464.
23. Oliviera AG, de Giacomelli FC, Giacomelli C, Spinelli A. (2005). Microstructure and surface composition effects on the transpassivation of NiTi wires for implant purposes. J Braz Chem Soc, 16: 131-138.
24. Dortunc B, Ozer L, Uyanik N. (1998). Development and in vitro evaluation of a buccoadhesive pindolol tablet formulation. Drug Dev Ind Pharm, 24:281-288.
25. Jasti BR, Zhou S, Mehta RC, Li X. (2000). Permeability of antisense oligonucleotide through porcine buccal mucosa. Int J Pharm, 208:35-39.
26. Narendra C, Srinath MS, Prakash Rao B. (2005). Development of three layered buccal compact containing metoprolol tartrate by statistical optimization technique. Int J Pharm, 304:102-114.
27. Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123-133.
28. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. (2001). Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm, 51:93-109.
29. Kitano M, Maitani Y, Takayama K, Nagai T. (1998). Buccal absorption through golden hamster cheek pouch in vitro and in vivo of 17'-estradiol from hydrogels containing three types of absorption enhancers. Int J Pharm. 174: 19-28.
30. Hokama N, Hobara N, Kameya H, Ohshiro S, Sakanashi M. (1999). Rapid and simple micro-determination of carvedilol in rat plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl, 732:233-238.
31. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G et al. (2006). Nasal administration of carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm, 307:9-15.
32. Otter K, Mignat C. (1998). Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl, 708:235-241.
33. Moffat AC, Osselton MD, Widdop B. (2005). Monograph-Pravastatin sodium, HMG Coenzyme reductase inhibitor. Clarke's analysis of drugs and poisons, London, UK: Pharmaceutical press.
34. Chast F, Bardin C, Sauvageon-Martre H, Callaert S, Chaumeil JC. (1991). Systemic morphine pharmacokinetics after ocular administration. J Pharm Sci, 80:911-917.
35. Miyazaki S, Nakayama A, Oda M, Takada M, Attwood M. (1995). Drug release from mucosal adhesive tablets of chitosan and sodium alginate. Int J Pharm. 118: 257-263.
36. Nakayama S, Sakashita M, Tonooka M, Gotoh H, Yasuhara H, Sakamoto K. (1983). Experimental hyperlipidemia and atherosclerosis induced by cholesterol diet in SPF Japanese white rabbits. Jpn J Pharmacol, 33:279-289.
37. Sakamoto K, Yamauchi M, Nakayama S, Tsuruzoe N, Sakashita M, Fujikawa Y. (1987). [Effect of NIP-200 on hyperlipidemia and atherosclerosis in cholesterol-fed rabbits]. Nippon Yakurigaku Zasshi, 90:187-193.
38. Kolodgie FD, Katocs AS Jr, Largis EE, Wrenn SM, Cornhill JF, Herderick EE et al. (1996). Hypercholesterolemia in the rabbit induced by feeding graded amounts of low-level cholesterol. Methodological considerations regarding individual variability in response to dietary cholesterol and development of lesion type. Arterioscler Thromb Vasc Biol, 16:1454-1464.
39. Yong CS, Jung JH, Rhee JD, Kim CK, Choi HG. (2001). Physicochemical characterization and evaluation of buccal adhesive tablets containing omeprazole. Drug Dev Ind Pharm, 27:447-455.
40. Nafee NA, Ismail FA, Boraie NA, Mortada LM. (2004). Mucoadhesive delivery systems. II. Formulation and in-vitro/invivo evaluation of buccal mucoadhesive tablets containing watersoluble drugs. Drug Dev Ind Pharm, 30:995-1004.
41. Andrews GP, Laverty TP, Jones DS. (2009). Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm, 71:505-518.
42. Khan TA, Peh KK, Chng HS. (2000). Mechanical, bioadhesive strength, biological evaluations of chitosan films for wound dressing. J Pharm Pharmaceu Sci. 3: 303-311.
43. Desai KG, Kumar TM. (2004). Preparation and evaluation of a novel buccal adhesive system. AAPS PharmSciTech, 5:e35.
44. Aungst B, Rogers N. (1989). Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery. Int J Pharm. 53: 227-235.
45. Shojaei AH, Berner B, Xiaoling L. (1998). Transbuccal delivery of acyclovir: I. In vitro determination of routes of buccal transport. Pharm Res, 15:1182-1188.
46. Agarwal V, Mishra B. (1999). Design, development, and biopharmaceutical properties of buccoadhesive compacts of pentazocine. Drug Dev Ind Pharm, 25:701-709.
47. Attia MA, El-Gibaly I, Shaltout SE, Fetih GN. (2004). Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels. Int J Pharm, 276:11-28.
48. Singh B, Ahuja N. (2002). Development of buccoadhesive hydrophilic matrices of diltiazem hydrochloride: Optimization of bioadhesion, dissolution and diffusion parameters. Drug Dev Ind Pharm. 28: 431-444.
49. Kuroda M, Matsumoto A, Itakura H, Watanabe Y, Ito T, Shiomi M et al. (1992). Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits. Jpn J Pharmacol, 59:65-70.